| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2798011 | Diabetes Research and Clinical Practice | 2008 | 7 Pages |
Abstract
In overweight non-diabetic people rosiglitazone reduces oxidative stress and improves insulin sensitivity. Rosiglitazone also improves first and second phase insulin secretion and reduces markers of inflammation and GGT.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Patrick J. Manning, Wayne H.F. Sutherland, Robert J. Walker, Sheila M. Williams, Sylvia A. de Jong, Elizabeth A. Berry,